Related coverage linked through entity extraction aliases.
Jun 16, 2026
The FDA has approved three new targeted therapies for different stages of advanced prostate cancer: Truqap for PTEN-deficient tumors, rucaparib for BRCA-mutated castration-resistant disease, and Akeega for BRCA2-mutated castration-sensitive cancer.
Jun 01, 2026
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
Mar 03, 2026
New initiatives aim to address social determinants of health in oncology, while research reveals persistent disparities in treatment access and clinical trial participation for Black and minority cancer patients.
